期刊文献+

A novel target to turn cold tumors into hot tumors: lysosomal 25-hydroxycholesterol activates AMPKα and immunosuppressive tumor-associated macrophages

原文传递
导出
摘要 In a recent issue of Immunity,Xiao et al.reported that cholesterol 25-hydroxylase(CH25H)is a novel immunometabolic checkpoint and a potential drug target for tumor immunotherapy[1].Their study elucidated how CH25H influences macrophage polarization and reshapes the tumor microenvironment(TME)by regulating the lysosomal 25-hydroxycholesterol(25HC)content and AMPKa activation(Fig.1).Fehleisen and Busch,two physicians from Germany,independently observed significant tumor regression following erysipelas infection in the late 19th century,and they provided the earliest scientific evidence for tumor immunotherapy[2].To date,immunotherapy has emerged as a focal point in cancer treatment,with the concept of the TME pivotal for understanding cancer initiation and progression[3].
出处 《Cellular & Molecular Immunology》 SCIE CAS CSCD 2024年第8期801-803,共3页 中国免疫学杂志(英文版)
基金 National Natural Science Foundation of China(Project:32371243,32171168,32350610248).
关键词 CHOLESTEROL al. cancer
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部